Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells 536 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 536 shares of BioLife Solutions stock in a transaction on Monday, July 7th. The stock was sold at an average price of $22.27, for a total transaction of $11,936.72. Following the completion of the transaction, the executive vice president owned 352,582 shares in the company, valued at approximately $7,852,001.14. The trade was a 0.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioLife Solutions Trading Down 1.0%

BioLife Solutions stock traded down $0.22 during mid-day trading on Wednesday, reaching $22.33. 352,995 shares of the company traded hands, compared to its average volume of 421,076. The firm's 50 day moving average price is $22.45 and its 200 day moving average price is $24.40. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -77.00 and a beta of 1.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.73 and a quick ratio of 3.74. BioLife Solutions, Inc. has a 52-week low of $18.70 and a 52-week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The firm had revenue of $23.94 million for the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. On average, analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, BioLife Solutions currently has an average rating of "Moderate Buy" and an average price target of $31.17.

Institutional Trading of BioLife Solutions

Hedge funds and other institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC bought a new position in BioLife Solutions in the 4th quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in BioLife Solutions during the fourth quarter valued at approximately $31,000. State of Wyoming lifted its position in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 1,490 shares during the period. US Bancorp DE lifted its position in BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 1,528 shares during the period. Finally, 1620 Investment Advisors Inc. lifted its position in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 675 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.